Celltrion\u2019s Herzuma was the first biosimilar of Roche\u2019s Herceptin, a blockbuster HER2-targeted therapy, to launch in Europe. A few months later, two additional trastuzumab biosimilars launched in Europe: Merck & Co.\u2019s Ontruzant and Amgen\u2019s Kanjinti. This series tracks uptake of these trastuzumab biosimilars and medical oncologists\u2019 awareness of these agents in order to gauge their impact on the commercially lucrative breast cancer and gastroesophageal cancer markets. The series investigates perceptions of trastuzumab biosimilars, drivers of and barriers to their use, and future use expectations. Promotional efforts, prescriber and nonprescriber profiles, and benchmarking of these agents\u2019 launch success versus other launched biosimilars are explored to better understand the dynamics of the German biosimilars market.<\/p>\n
QUESTIONS ANSWERED<\/strong><\/p>\n PRODUCT DESCRIPTION<\/strong><\/p>\n Emerging Biosimilars <\/em>(Germany) is a three-wave series based on primary research data collected at 1 month, 6 months, and 12 months post-commercial launch with German physicians. The research captures physicians\u2019 awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.<\/p>\n RELEASE DATE<\/strong><\/p>\n Wave 1: September 2018.<\/p>\n Wave 2: February 2019.<\/p>\n Wave 3: July 2019.<\/p>\n GEOGRAPHY<\/strong><\/p>\n Germany.<\/p>\n PRIMARY RESEARCH<\/strong><\/p>\n A survey of 60 medical oncologists.<\/p>\n Key metrics included<\/strong><\/p>\n\n
\n